Pan-HA ANTIBODIES CONFER PROTECTION IN MICE AGAINST INFLUENZA

Aziza Manceur, National Research Council Canada
Aziza.manceur@nrc.ca
Wangxue Chen, Amalia Ponce, National Research Council Canada
Anne Marcil, Wei Zou, National Research Council Canada
Gilles St-Laurent, Yves Durocher, National Research Council Canada
Mélanie Leclerc, Parminder Chahal, National Research Council Canada
Sven Ansorge, Marie-Hélène Venne, National Research Council Canada
Viktoria Lytvyn, Rénal Gilbert, National Research Council Canada

Key Words: Influenza, Hemagglutinin, Universal antibodies, Adeno-associated virus, CHO

The elderly population is one of the most vulnerable groups to influenza infection and influenza-related complications. Unfortunately, vaccination exhibits reduced efficacy in this population. Immunization and treatment with passive antibody transfer could therefore be a valuable alternative.

In this project, we have generated antibodies against a constant region of hemagglutinin (HA), the main protein found at the surface of the virus. In vitro, two lead candidates (mAb 10A9 and mAb 11H12) were able to detect strains belonging to 13 subtypes of Influenza A as well as B strains (1). In order to facilitate large scale production, stable CHO pools were generated for pan-HA antibody production. Biophysical characteristics of antibodies produced in CHO cells were similar to the ones of antibodies generated using mouse hybridomas. The antibodies were further tested in a mouse model of influenza to evaluate their protective potential.

The antibodies offered protection against influenza regardless of their production platform (Figure 1). The CHO-produced antibody was tested in prophylactic mode (first injection 24hrs before the challenge) and as a therapeutic (first treatment 4hrs after viral infection). In both cases, all mice survived. Other viral strains and treatment regimens have to be tested but these preliminary results are encouraging.

Finally, multiple repeated administrations of the mAb in at-risk population would be impractical and too expensive. Therefore, recombinant Adeno-Associated-Virus (rAAV) is being considered as a delivery system. Using rAAV would allow delivering the genes encoding for the mAb and ensuring their long-term expression. The heavy chain and light chain of the pan-HA antibodies are expressed on the same cassette and transfected into suspension HEK293SF cells, along with two other plasmids to form the AAV particles. After purification, the AAV will be injected in mice for long term production of the antibodies (experiments ongoing). This would represent a cost effective delivery route in immunocompromised or elderly individuals.